Research shows that a lack of insurance leads to worse cancer outcomes for patients 60-64 compared to Medicare beneficiaries aged 66-69. This work highlights the fact that many people cannot take advantage of potentially lifesaving treatments due to the high costs.
Early preterm births may be dramatically decreased with docosahexaenoic acid (DHA) supplements, with a dose of 1000 mg more effective for pregnant women with low DHA levels than the 200 mg found in some prenatal supplements.
A team of Welsh academics has developed a new method of supporting health professionals to make clinical decisions about people who may be at risk of taking their own lives.
The American College of Cardiology's (ACC) Global Heart Attack Treatment Initiative (GHATI) had measurable positive impacts on care delivery for heart attacks in low- and middle-income countries, according to data from the program's first year. Results were presented at the ACC's 70th Annual Scientific Session.
In a study of low-income, urban youth in the U.S., researchers at Columbia University Mailman School of Public Health found that students exposed to Photovoice, an educational intervention, experienced greater improvements in STEM-capacity scores and environmental awareness scores compared to a group of youth who were not exposed to the activity. The results suggest that the Photovoice activities may be associated with improved learning outcomes.
The likelihood of people surviving COVID-19 in UK hospitals has been improving over time, a new study has found. Research published in The Lancet Respiratory Medicine by the ISARIC Coronavirus Clinical Characterisation Consortium found that in-hospital mortality declined from 32% at the start of the first wave (Mar-Apr 2020) to 16% at the end of the first wave (Jun-Jul 2020).
The experimental heart failure drug omecamtiv mecarbil reduced heart failure hospitalizations by a greater margin among patients with more severely reduced ejection fraction, a measure indicating severe impairment in the heart's pumping ability, compared with those who had moderately reduced ejection fraction, according to research presented at the American College of Cardiology's 70th Annual Scientific Session.
Patients with heart failure with preserved ejection fraction who took the antifibrotic drug pirfenidone saw a significant reduction in a marker of heart muscle scarring compared with patients who received a placebo, based on findings from an early-phase trial presented at the American College of Cardiology's 70th Annual Scientific Session.
Patients with heart failure with reduced ejection fraction (HFrEF) did not have better health outcomes if they took sacubitril/valsartan combination therapy compared with valsartan alone, according to new data presented at the American College of Cardiology's 70th Annual Scientific Session.
A program designed to improve hospital care for patients with heart failure, the leading cause of hospitalization among adults over age 65, did not bring additional benefits beyond existing hospital quality improvement programs in a randomized controlled trial presented at the American College of Cardiology's 70th Annual Scientific Session.